If efficiently and safely scaled up in DMD patients, this technique could lead to one of the first successful genome editing-based treatments for this fatal disease, researchers said.
DMD, the most common and severe form of muscular dystrophy among boys, is characterized by progressive muscle degeneration and weakness. It is caused by mutations in the X-linked DMD gene that encodes the protein dystrophin. The disease affects one in 3,500 to 5,000 boys, according to the Centers for Disease Control and Prevention and other estimates, and often leads to premature death by the early 30s.
Although the genetic cause of DMD has been known for nearly 30 years, no effective treatments exist. The disease breaks down muscle fibers and replaces them with fibrous or fatty tissue, causing the muscle to gradually weaken. This condition often results in heart muscle disease, or cardiomyopathy, the leading cause of death in these patients.
In the study published today in Science, UTSW researchers used a gene-editing approach to permanently correct the DMD mutation that causes the disease in young mice.
“This is different from other therapeutic approaches, because it eliminates the cause of the disease,” said senior author Dr. Eric Olson, Chairman of Molecular Biology, and Co-Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center at UT Southwestern.
In 2014, Dr. Olson’s team first used this technique – called CRISPR/Cas9-mediated genome editing – to correct the mutation in the germ line of mice and prevent muscular dystrophy. This paved the way for novel genome editing-based therapeutics in DMD. It also raised several challenges for clinical applications of gene editing. Since germ line editing is not feasible in humans, strategies would need to be developed to deliver gene-editing components to postnatal tissues.
To test this out, researchers delivered gene-editing components to the mice via adeno-associated virus 9 (AAV9). DMD mice treated with this technique produced dystrophin protein and progressively showed improved structure and function of skeletal muscle and heart.
“AAV9 can efficiently infect humans in a tissue-specific manner, but it does not cause human disease or toxicity. It’s a molecular missile for gene therapy,” said Dr. Leonela Amoasii, a postdoctoral researcher in the Olson lab and co-lead author of the study with Dr. Chengzu Long, Instructor of Molecular Biology.
“The CRISPR/Cas9 system is an adaptive immune system of single-celled organisms against invading virus. Ironically, this system was hijacked, we packaged it into a nonpathogenic virus, and corrected a genetic mutation in an animal model,” added Dr. Long.
The CRISPR genome-editing technology, which was developed by a researcher at University of California at Berkeley, was picked as the “Breakthrough of the Year” scientific development by Science.
“This study represents a very important translational application of genome editing of DMD mutations in young mice. It’s a solid step toward a practical cure for DMD,” said Dr. Rhonda Bassel-Duby, Professor of Molecular Biology and Co-Principal Investigator of a genomic editing project with Dr. Olson at the Wellstone Center.
“Importantly, in principle, the same strategy can be applied to numerous types of mutations within the human DMD patients,” added Dr. Olson, who also serves as Director of the Hamon Center for Regenerative Science and Medicine, and holds the Annie and Willie Nelson Professorship in Stem Cell Research, the Pogue Distinguished Chair in Research on Cardiac Birth Defects, and the Robert A. Welch Distinguished Chair in Science.
Now, the research team is working to apply this gene-editing technique to cells from DMD patients and in larger preclinical animal models.
The Latest on: Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Duchenne muscular dystrophy
- Muscular Dystrophy: Symptoms, causes, diagnosis and treatmenton February 22, 2024 at 3:27 am
These mutations can occur in various genes, each associated with a specific type of Muscular Dystrophy. The most common types include: Duchenne Muscular Dystrophy (DMD): Caused by mutations in the ...
- Spennymoor teen cares for his brother with muscle conditionon February 21, 2024 at 10:00 pm
William described as ‘funny, caring, charming and super bright’ has selflessly taken on the role of providing care and support for his younger brother Louis, 12, who was diagnosed with Duchenne ...
- Staten Island JAR of Hope donates nearly $12K to CrimsonRise to help those with autism communicateon February 21, 2024 at 8:59 pm
STATEN ISLAND, N.Y. — JAR of Hope, an organization that raises funds to research a cure for kids with Duchenne muscular dystrophy — that’s recently expanded its mission statement to include kids on ...
- Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?on February 21, 2024 at 8:24 am
We expect Sarepta Therapeutics SRPT to beat expectations when it reports fourth-quarter and full-year 2023 results. In the last reported quarter, the company delivered an earnings surprise of ...
- Herpes-Dementia Link; How COVID Affects the Brain; FDA to Decide on Duchenne Drugon February 20, 2024 at 11:54 am
German researchers showed that SARS-CoV-2 did not persist in brain cells and supported the idea that COVID's neurologic complications may be due to inflammatory immune reactions. ( Nature Neuroscience ...
- Novel ASO screening study paves the way for duchenne muscular dystrophy (DMD) therapy advancementson February 20, 2024 at 2:11 am
This article talks about the identification of a novel ASO (AON-C19) which opens a promising new avenue for Duchenne Muscular Dystrophy (DMD) therapy development.
- Santhera’s Duchenne muscular dystrophy drug shows promise as long-term treatmenton February 19, 2024 at 4:27 am
Santhera Pharmaceuticals has announced the publication of results in the journal Neurology that support the long-term efficacy and safety profile of its Duchenne muscular dystrophy (DMD) drug, Agamree ...
- The Future of Medicine Is Unfolding Before Us. Are We Nurturing It?on February 18, 2024 at 9:02 pm
Before Eliot received his treatment, he had difficulty going up stairs. He complained about being tired after walking only a block or two, even on Halloween when candy ought to have motivated him.
- Duchenne Muscular Dystrophy Market Size Predicted To Hit USD 2.1 Billion By 2031 At 4.7% CAGR, Says AMRon February 13, 2024 at 10:33 pm
Duchenne Muscular Dystrophy Market 2024 Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healt ...
- Positive Phase 2 Data for SRP-5051 in Duchenne Muscular Dystrophyon February 12, 2024 at 4:00 pm
The Momentum trial from Sarepta Therapeutics is investigating SRP-5051 (vesleteplirsen) for use among male patients aged 8 to 21 years who have Duchenne muscular dystrophy amenable to exon 51 skipping ...
via Bing News